- The 8 States Most Likely to Legalize Marijuana Next
- BlackBerry Is Finally Realizing Smartphones Aren't the Answer
- Express Scripts and AbbVie Drug-Pricing Deal Might Devastate Biotech Bull Market
- Dow 18,000: Why This Market Rally May Never Happen Again
- Gilead Sciences Is Not a Buy; It's Heading Lower on Price War: Jim Cramer
Cramer prefers Federal Realty over Kite Realty Group, Rangold over Yamana Gold and regrets not being more aggressive on Prudential Financial.
Cramer will be watching Chinese economic data, company earnings and other things to get investors excited next week.
Cramer prefers Celgene over Gilead Sciences, Palo Alto Networks over OSI Systems and is discouraged by IBM.
People obsessed with the Fed have kept you out of the market, Cramer said, and the Fed's bond buyback tapering is simply not having an impact.
Cramer is avoiding Linn Energy but likes Crestwood Midstream.
It's not a mistake for the bulls to be complacent -- if they happen to be right, Cramer said.
Cramer thinks Westlake Chemical is a winner but he's staying away from Smith & Wesson.
The market reacted correctly to the continued tensions in Iraq and the effect on oil, Cramer said.
Cramer favors Moody's and Magnum Hunter but is staying away from Molycorp and Coupons.com.
With uncertainty in the market, the best strategy is investing in quality, Cramer said.